Dergiler / The Anatolian Journal of Cardiology / 2018 / Cilt: 20 - Sayı: 1

Anemia in heart failure - from guidelines to controversies and challenges

Sayfa
52–59
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Thispaper is focused on data about anemia in heart failure, from prevalence to optimal treatment, controversies, and challenges.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Anemia associated with heart failure is a frequent condition, which may lead to heart function deterioration by the activation of neuro-hormonalmechanisms.
📊
Temel Bulgular & Veri:Therefore, a vicious circle is present in the relationship of heart failure and anemia.
💡
Sonuç & Katkı:Thispaper is focused on data about anemia in heart failure, from prevalence to optimal treatment, controversies, and challenges.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Anemia associated with heart failure is a frequent condition, which may lead to heart function deterioration by the activation of neuro-hormonalmechanisms. Therefore, a vicious circle is present in the relationship of heart failure and anemia. The consequence is reflected upon the patients’survival, quality of life, and hospital readmissions. Anemia and iron deficiency should be correctly diagnosed and treated in patients withheart failure. The etiology is multifactorial but certainly not fully understood. There is data suggesting that the following factors can cause anemiaalone or in combination: iron deficiency, inflammation, erythropoietin levels, prescribed medication, hemodilution, and medullar dysfunction.There is data suggesting the association among iron deficiency, inflammation, erythropoietin levels, prescribed medication, hemodilution,and medullar dysfunction. The main pathophysiologic mechanisms, with the strongest evidence-based medicine data, are iron deficiency andinflammation. In clinical practice, the etiology of anemia needs thorough evaluation for determining the best possible therapeutic course. In thiscontext, we must correctly treat the patients’ diseases; according with the current guidelines we have now only one intravenous iron drug. Thispaper is focused on data about anemia in heart failure, from prevalence to optimal treatment, controversies, and challenges.

🔖

Bu Makaleye Atıf Yap

SÎRBU, O., FLORİA, M., DASCALİTA, P., STOİCA, A., ADASCALİTEİ, P., ŞORODOC, V., ŞORODOC, L. (2018). Anemia in heart failure - from guidelines to controversies and challenges. The Anatolian Journal of Cardiology, Cilt: 20 - Sayı: 1, 52–59. https://ajindex.com/articles/367227

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

  1. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 2016; 18: 786-95. [CrossRef] Kapoor M, Schleinitz MD, Gemignani A, Wu WC. Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: a meta-analysis. Cardiovasc Hematol Disord Drug Targets 2013; 13: 35-44. [CrossRef] Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail 2012; 14: 423-9. [CrossRef] Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J 2015; 36: 657-68.
  2. Gaber R, Kotb NA, Ghazy M, Nagy HM, Salama M, Elhendy A. Tissue Doppler and strain rate imaging detect improvement of myocardial function in iron deficient patients with congestive heart failure after iron replacement therapy. Echocardiography 2012; 29: 13-8. [CrossRef] Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-48. [CrossRef] Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51: 103-12.
  3. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008; 21: 236-42.
  4. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007; 50: 1657-65. [CrossRef] Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48: 1225-7.
  5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF